Soligenix announces promising results in extended HyBryte treatment study for cutaneous T-cell lymphoma
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, has shared an interim update on a key study involving extended HyBryte treatment in patients with early-stage ... Read More
Soligenix all set to begin FLASH clinical trial for SGX301 in CTCL
US biopharma company Soligenix has wrapped up enrolling patients for its phase 3 Fluorescent Light Activated Synthetic Hypericin clinical trial (FLASH clinical trial) for SGX301 ... Read More